鹭燕医药(002788) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 4,841,503,352.57, representing a 4.40% increase compared to CNY 4,637,268,373.59 in the same period last year[5] - Net profit attributable to shareholders was CNY 79,861,688.20, an increase of 11.37% from CNY 71,706,561.12 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 4,841,503,352.57, an increase of 4.4% compared to CNY 4,637,268,373.59 in Q1 2022[23] - Net profit for Q1 2023 reached CNY 78,600,499.56, compared to CNY 71,333,431.99 in Q1 2022, representing a growth of 10.1%[24] - The net profit attributable to the parent company was CNY 79,861,688.20, an increase from CNY 71,706,561.12 in the previous year, marking a rise of 11.5%[24] - Basic earnings per share for Q1 2023 were CNY 0.21, up from CNY 0.18 in Q1 2022[24] Cash Flow - The net cash flow from operating activities increased by 127.21%, reaching CNY 113,401,415.76, compared to a negative cash flow of CNY -416,697,576.75 in the previous year[5] - Cash inflow from operating activities totaled ¥5,408,013,910.72, compared to ¥4,650,047,143.44 in the prior period, reflecting a year-over-year increase of approximately 16.3%[27] - Cash outflow from operating activities was ¥5,294,612,494.96, up from ¥5,066,744,720.19, indicating a rise of about 4.5%[27] - The ending balance of cash and cash equivalents was ¥341,124,938.55, up from ¥255,336,795.43, marking an increase of approximately 33.5%[28] - The company paid ¥68,752,595.94 in dividends and interest, compared to ¥44,527,421.71 in the previous period, reflecting a rise of about 54.3%[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,349,841,193.41, a decrease of 3.68% from CNY 11,783,796,364.82 at the end of the previous year[5] - Total liabilities decreased to CNY 8,488,723,106.98 from CNY 8,993,147,283.00 year-on-year[21] - The company's total equity increased to CNY 2,861,118,086.43, compared to CNY 2,790,649,081.82 in the previous year[21] - Total current assets decreased from 9.75 billion yuan to 9.29 billion yuan, a decline of approximately 4.7%[17] Accounts Receivable and Inventory - Accounts receivable increased by 604.75% to CNY 3,347,600.00, primarily due to received bills not being endorsed or discounted[9] - Accounts receivable increased slightly from 5.84 billion yuan to 5.85 billion yuan, indicating a marginal growth of 0.03%[17] - Inventory decreased from 2.55 billion yuan to 2.38 billion yuan, representing a reduction of about 6.7%[17] Legal Matters - The company has initiated legal proceedings to recover 39.69 million yuan in damages from Guizhou Mingrun Construction Engineering Co., Ltd. and Chengdu Hechuang Ruida Enterprise Management Co., Ltd.[16] - The company has successfully enforced the collection of 8 million yuan in breach of contract damages from Guizhou Mingrun Construction Engineering Co., Ltd.[15] - Chengdu Hechuang has filed a new lawsuit seeking compensation of 31.63 million yuan plus interest from the aforementioned companies[16] Research and Development - Research and development expenses for Q1 2023 were CNY 769,300.60, up from CNY 602,864.18 in Q1 2022, indicating a focus on innovation[23] Other Financial Metrics - The company reported a decrease in other comprehensive income, with a net amount of CNY -441,714.34 for Q1 2023 compared to CNY -279,198.76 in Q1 2022[24] - The company reported a significant increase in other current assets, which rose by 67.05% to CNY 66,615,100.00, attributed to an increase in input tax credits[9] - The balance of prepayments decreased by 37.71% to CNY 391,556,800.00, mainly due to the settlement of a large amount of prepaid epidemic prevention material payments[9] - The company has actively explored new financing tools such as supply chain financing and factoring, contributing to improved cash flow management[9]